Pityriasis rubra pilaris-like erythroderma secondary to phosphoinositide 3-kinase inhibition

Clinical and Experimental Dermatology
A K DewanN R LeBoeuf

Abstract

Phosphoinositide 3-kinase (PI3K) inhibitors are a class of small-molecule inhibitors approved for the treatment of certain leukaemias and lymphomas. Their dermatological adverse event profile is poorly described. To characterize a rare cutaneous adverse event from PI3K inhibitors in order to help dermatologists and oncologists identify and effectively manage such eruptions. This was a retrospective analysis of patients receiving PI3K inhibitors referred to the Skin Toxicities Program in The Center for Cutaneous Oncology. Three patients on PI3K inhibitors for treatment of malignancy developed diffuse erythroderma and keratoderma. Clinical and histopathological findings were consistent with pityriasis rubra pilaris (PRP)-like reactions. All patients improved with topical and oral corticosteroids, oral acitretin, and drug discontinuation. PRP-like cutaneous eruptions may develop secondary to PI3K inhibition. Early dermatological evaluation of cutaneous toxicities to PI3K inhibitors as well as rapid initiation of disease-specific treatments may help keep patients on life-prolonging anti-cancer therapies.

References

May 1, 1987·Pediatric Dermatology·D ShviliM Mimouni
Dec 13, 2005·Nature Reviews. Drug Discovery·Bryan T HennessyGordon B Mills
Nov 4, 2006·The Journal of Immunology : Official Journal of the American Association of Immunologists·Daniel T PattonKlaus Okkenhaug
Feb 27, 2010·American Journal of Clinical Dermatology·Annette KleinSigrid Karrer
Apr 10, 2010·Nature Reviews. Molecular Cell Biology·Bart VanhaesebroeckBenoit Bilanges
Jun 18, 2011·European Journal of Dermatology : EJD·Antonio Giovanni RichettaStefania Morrone
Dec 14, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Johanna C BendellJosé Baselga
Sep 15, 2015·Acta Pharmacologica Sinica·Xiang WangLing-hua Meng
Oct 16, 2016·Journal of the European Academy of Dermatology and Venereology : JEADV·J BonigenUNKNOWN Groupe de Recherche sur le Psoriasis and the Groupe Cancérologie Cutanée of the Société Française de Dermatologie the GEM Re
Oct 21, 2016·JAMA Dermatology·Takuya TakeichiMasashi Akiyama
Jan 26, 2017·JAMA Dermatology·Laurence FeldmeyerCurdin Conrad

❮ Previous
Next ❯

Citations

May 19, 2020·American Society of Clinical Oncology Educational Book·Carey K AndersAlexandra Thomas
Jan 26, 2020·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Maria VastarellaVincent Sibaud
Jul 21, 2020·Journal of the American Academy of Dermatology·Asfandyar MuftiJensen Yeung
Oct 9, 2021·Journal of Cutaneous Pathology·Riyad N H SeervaiJonathan L Curry

❮ Previous
Next ❯

Related Concepts

Related Feeds

B-Cell Leukemia (Keystone)

B-cell leukemia includes various types of lymphoid leukemia that affect B cells. Here is the latest research on B-cell leukemia.

AKT Pathway

This feed focuses on the AKT serine/threonine kinase, which is an important signaling pathway involved in processes such as glucose metabolism and cell survival.

Related Papers

Acta Dermato-venereologica
K B Sørensen, Kristian Thestrup-Pedersen
Annales de dermatologie et de vénéréologie
M Chaabouni
Journal of the European Academy of Dermatology and Venereology : JEADV
E SelvaagK Thomsen
Archivio italiano di dermatologia, sifilografia, e venereologia
P PARISI
© 2022 Meta ULC. All rights reserved